

June 27, 2025

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") regarding designation as Senior Management Personnel of the Company

Pursuant to Regulation 30 of the Listing Regulations, we hereby inform you that Dr. Vinayak Dinkar Kadam has been designated as a Senior Management Personnel of the Company with effect from 27th June, 2025 consequent to his appointment as Associate Vice President – FR&D, Tichel Biopark. He will be responsible for overseeing the Company's Formulation Research and Development.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed as "Annexure- A".

This is for your kind information and records.

Thanking You,

Sincerely yours,

For **Caplin Point Laboratories Limited**

Venkatram G

General Counsel & Company Secretary

Membership No. A23989

Annexure – A

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Dr. Vinayak Dinkar Kadam as Associate Vice President – FR&D, Ticel Biopark
2.	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/ re-appointment ;	June 27, 2025 Term: Full-time employment
3.	Brief profile	Dr. Vinayak Dinkar Kadam holds a Ph.D and M. Pharm in Pharmaceutics and he is an accomplished pharmaceutical R&D professional with over 20 years of experience in formulation and development of all types of solid and liquid dosages, including ophthalmic products for regulated markets including the US and EU.
4.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable